Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.
Interdepartmental Division of Critical Care Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Lancet Respir Med. 2018 Nov;6(11):874-884. doi: 10.1016/S2213-2600(18)30326-6.
As a result of technical improvements, extracorporeal carbon dioxide removal (ECCOR) now has the potential to play an important role in the management of adults with acute respiratory failure. There is growing interest in the use of ECCOR for the management of both hypoxaemic and hypercapnic respiratory failure. However, evidence to support its use is scarce and several questions remain about the best way to implement this therapy, which can be associated with serious side-effects. This Review reflects the consensus opinion of an international group of clinician scientists with expertise in managing acute respiratory failure and in using ECCOR therapies in this setting. We concisely review clinically relevant aspects of ECCOR, and provide a series of recommendations for clinical practice and future research, covering topics that include the practicalities of ECCOR delivery, indications for use, and service delivery.
由于技术的进步,体外二氧化碳去除(ECCOR)现在有可能在成人急性呼吸衰竭的治疗中发挥重要作用。人们对 ECCOR 用于治疗低氧血症和高碳酸血症性呼吸衰竭越来越感兴趣。然而,支持其使用的证据很少,并且对于如何最好地实施这种治疗方法仍存在一些问题,因为这种治疗可能会引起严重的副作用。这篇综述反映了一组具有管理急性呼吸衰竭和在该环境中使用 ECCOR 治疗专业知识的国际临床科学家小组的共识意见。我们简明地回顾了 ECCOR 的临床相关方面,并为临床实践和未来研究提供了一系列建议,涵盖了 ECCOR 输送的实用性、使用指征和服务提供等主题。